Intravenous immune globulin (IVIg) is a widely used immune modulating therapy for idiopathic and post-infectious autoimmune disorders where the immune system goes awry, leaving in its wake, tandem central, peripheral and autonomic nervous system dysfunction.
The 2019 novel coronavirus (2019‐nCoV [COVID-19]) epidemic, the third known zoonotic coronavirus disease after severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS) is now know to be caused by coronavirus 2 (SARS‐CoV‐2). The SARS‐CoV‐2 virus probably originated in bats from which it transmitted to humans. Epidemic transmission is caused by human-to-human transmission.
Intravenous immune globulin (IVIg) is the most widely employed immune modulating agent for autoimmune disorders. It treats post-infectious disorders where the immune system goes awry, causing injury to organs of the body due to post-infectious and non-infectious autoimmunity. The nervous system is particularly vulnerable to autoimmune diseases and IVIg therapy.
Read about the successful use of hydroxychloroquine (Plaquenil) and azithromycin (Zithromax) in the treatment of Coronavirus (COVID-19) in an open label non-randomized French clinical trial.